Drug Profile
Bortezomib nanoparticle - Tharimmune
Alternative Names: HBP-407; HSB-407Latest Information Update: 15 Jan 2024
Price :
$50
*
At a glance
- Originator Hillstream BioPharma
- Developer Tharimmune
- Class Amides; Anti-ischaemics; Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules; Vascular disorder therapies
- Mechanism of Action Apoptosis stimulants; NF-kappa B inhibitors; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 31 Jul 2017 Chemical structure information added
- 12 Jun 2017 Preclinical trials in Cancer in USA (unspecified route)